Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Current Practice in Immunosuppression in Pediatric Liver Transplantation

Author(s): Rodrigo Vincenzi, Eduardo A. Fonseca, Karina M. O. Roda, Paulo Chapchap and João Seda Neto*

Volume 26, Issue 28, 2020

Page: [3402 - 3405] Pages: 4

DOI: 10.2174/1381612826666200614181526

Price: $65

Abstract

The last decades have witnessed a significant improvement in the field of pediatric liver transplantation (LT), resulting in longer patient and graft survival; adequate graft selection, surgical refinement, the use of live donors and optimal postoperative care are among the reasons why pediatric recipients are living longer. With this new condition, pediatric recipients are now more exposed to the deleterious effects of immunosuppression, including metabolic, infectious and neoplastic complications, nephrotoxicity and neurotoxicity. Due to all those particularities, the approach to avoid overimmunosuppression or underimmunosuppression may be more difficult in children than in adult recipients. Moreover, pediatric recipients are exposed to growth issues and specific problems during adolescence, like nonadherence to immunosuppressive therapy. This article highlights the current immunosuppressive strategies for pediatric liver transplant recipients.

Keywords: Liver transplantation, pediatric transplantation, immunosuppression, acute cellular rejection, chronic rejection, solid-organ transplant.

« Previous Next »
[1]
Bucuvalas J. Long-term outcomes in pediatric liver transplantation. Liver Transpl 2009; 15(Suppl. 2): S6-S11.
[http://dx.doi.org/10.1002/lt.21915] [PMID: 19877291]
[2]
Kelly DA, Bucuvalas JC, Alonso EM, et al. American Association for the Study of Liver Diseases; American Society of Transplantation. Long-term medical management of the pediatric patient after liver transplantation: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19(8): 798-825.
[http://dx.doi.org/10.1002/lt.23697] [PMID: 23836431]
[3]
Kasahara M, Umeshita K, Inomata Y, Uemoto S. Japanese Liver Transplantation Society. Long-term outcomes of pediatric living donor liver transplantation in Japan: an analysis of more than 2200 cases listed in the registry of the Japanese Liver Transplantation Society. Am J Transplant 2013; 13(7): 1830-9.
[http://dx.doi.org/10.1111/ajt.12276] [PMID: 23711238]
[4]
Miloh T, Barton A, Wheeler J, et al. Immunosuppression in pediatric liver transplant recipients: Unique aspects. Liver Transpl 2017; 23(2): 244-56.
[http://dx.doi.org/10.1002/lt.24677] [PMID: 27874250]
[5]
McDiarmid SV, Anand R, Lindblad AS. SPLIT Research Group. Studies of Pediatric Liver Transplantation: 2002 update. An overview of demographics, indications, timing, and immunosuppressive practices in pediatric liver transplantation in the United States and Canada. Pediatr Transplant 2004; 8(3): 284-94.
[http://dx.doi.org/10.1111/j.1399-3046.2004.00153.x] [PMID: 15176967]
[6]
Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2017 Annual Data Report: Liver. Am J Transplant 2019; 19(Suppl. 2): 184-283.
[http://dx.doi.org/10.1111/ajt.15276] [PMID: 30811890]
[7]
Jain A, Mazariegos G, Kashyap R, et al. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. Transplantation 2000; 70(4): 617-25.
[http://dx.doi.org/10.1097/00007890-200008270-00015] [PMID: 10972220]
[8]
McDiarmid SV. Special considerations for immunosuppression in children transplantation of the liver. Liver Transplantation 2015; 1289-316.
[http://dx.doi.org/10.1016/B978-1-4557-0268-8.00092-0]
[9]
Spada M, Riva S, Maggiore G, Cintorino D, Gridelli B. Pediatric liver transplantation. World J Gastroenterol 2009; 15(6): 648-74.
[http://dx.doi.org/10.3748/wjg.15.648] [PMID: 19222089]
[10]
Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 2001; 40(4): 283-95.
[http://dx.doi.org/10.2165/00003088-200140040-00004] [PMID: 11368293]
[11]
Solari S, Cancino A, Wolff R, et al. Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study. Aliment Pharmacol Ther 2017; 45(9): 1225-31.
[http://dx.doi.org/10.1111/apt.14022] [PMID: 28261844]
[12]
Kelly D. Safety and efficacy of tacrolimus in pediatric liver recipients. Pediatr Transplant 2011; 15(1): 19-24.
[http://dx.doi.org/10.1111/j.1399-3046.2010.01437.x] [PMID: 21176018]
[13]
Tsampalieros A, Knoll GA, Molnar AO, Fergusson N, Fergusson DA. Corticosteroid use and growth after pediatric solid organ transplantation: a systematic review and meta-analysis. Transplantation 2017; 101(4): 694-703.
[http://dx.doi.org/10.1097/TP.0000000000001320] [PMID: 27736823]
[14]
Gras JM, Gerkens S, Beguin C, et al. Steroid-free, tacrolimus basiliximab immunosuppression in pediatric liver transplantation: clinical and pharmacoeconomic study in 50 children. Liver Transpl 2008; 14(4): 469-77.
[http://dx.doi.org/10.1002/lt.21397] [PMID: 18383091]
[15]
Aw MM, Verma A, Rela M, Heaton N, Mieli-Vergani G, Dhawan A. Long-term outcome of mycophenolate mofetil rescue therapy for resistant acute allograft rejection in pediatric liver transplant recipients. Liver Transpl 2008; 14(9): 1303-8.
[http://dx.doi.org/10.1002/lt.21530] [PMID: 18756458]
[16]
Barau C, Barrail-Tran A, Hemerziu B, et al. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. Liver Transpl 2011; 17(10): 1152-8.
[http://dx.doi.org/10.1002/lt.22364] [PMID: 21695772]
[17]
Evans HM, McKiernan PJ, Kelly DA. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation 2005; 79(11): 1575-80.
[http://dx.doi.org/10.1097/01.TP.0000163504.29054.3F] [PMID: 15940048]
[18]
Hendrickson RJ, Sujka J, Fischer R, Manalang M, Daniel J, Andrews WS. Indications and efficacy of conversion from tacrolimus to sirolimus-based immunosuppression in pediatric patients who underwent liver transplantation for unresectable hepatoblastoma. Pediatr Transplant 2019; 23(3) e13369
[http://dx.doi.org/10.1111/petr.13369] [PMID: 30719825]
[19]
Ventura-Aguiar P, Campistol JM, Diekmann F. Safety of mTOR inhibitors in adult solid organ transplantation. Expert Opin Drug Saf 2016; 15(3): 303-19.
[http://dx.doi.org/10.1517/14740338.2016.1132698] [PMID: 26667069]
[20]
Nielsen D, Briem-Richter A, Sornsakrin M, Fischer L, Nashan B, Ganschow R. The use of everolimus in pediatric liver transplant recipients: first experience in a single center. Pediatr Transplant 2011; 15(5): 510-4.
[http://dx.doi.org/10.1111/j.1399-3046.2011.01515.x] [PMID: 21696525]
[21]
Ueno T, Hiwatashi S, Saka R, et al. Everolimus rescue treatment for chronic rejection after pediatric living donor liver transplantation: 2 case reports. Transplant Proc 2018; 50(9): 2872-6.
[http://dx.doi.org/10.1016/j.transproceed.2018.03.079] [PMID: 30318104]
[22]
Ganschow R, Ericzon B-G, Dhawan A, et al. Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study. Pediatr Transplant 2017; 21(7)
[http://dx.doi.org/10.1111/petr.13024] [PMID: 28714558]
[23]
Turner AP, Knechtle SJ. Induction immunosuppression in liver transplantation: a review. Transpl Int 2013; 26(7): 673-83.
[http://dx.doi.org/10.1111/tri.12100] [PMID: 23651083]
[24]
Mouzaki M, Yap J, Avinashi V, et al. Basiliximab with delayed introduction of calcineurin inhibitors as a renal-sparing protocol following liver transplantation in children with renal impairment. Pediatr Transplant 2013; 17(8): 751-6.
[http://dx.doi.org/10.1111/petr.12158] [PMID: 24118898]
[25]
Spada M, Petz W, Bertani A, et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. Am J Transplant 2006; 6(8): 1913-21.
[http://dx.doi.org/10.1111/j.1600-6143.2006.01406.x] [PMID: 16771811]
[26]
Petite SE, Bollinger JE, Eghtesad B. Antithymocyte globulin induction therapy in liver transplant: old drug, new uses. Ann Pharmacother 2016; 50(7): 592-8.
[http://dx.doi.org/10.1177/1060028016647974] [PMID: 27147705]
[27]
Shepherd RW, Turmelle Y, Nadler M, et al. SPLIT Research Group. Risk factors for rejection and infection in pediatric liver transplantation. Am J Transplant 2008; 8(2): 396-403.
[http://dx.doi.org/10.1111/j.1600-6143.2007.02068.x] [PMID: 18162090]
[28]
Thangarajah D, O’Meara M, Dhawan A. Management of acute rejection in paediatric liver transplantation. Pediatric Drugs 2013; 15: 459-71.
[29]
Meng X, Gao W, Wang K, Han C, Zhang W, Sun C. Adherence to medical regimen after pediatric liver transplantation: a systematic review and meta-analysis. Patient Prefer Adherence 2018; 13: 1-8.
[http://dx.doi.org/10.2147/PPA.S181195] [PMID: 30587939]
[30]
McDiarmid SV. Adolescence: challenges and responses. Liver Transpl 2013; 19(Suppl. 2): S35-9.
[http://dx.doi.org/10.1002/lt.23740] [PMID: 24166838]
[31]
Quintero J, Juampérez J, Ortega J, et al. Conversion from twice daily to once-daily tacrolimus formulation in pediatric liver transplant recipients - a long-term prospective study. Transpl Int 2018; 31(1): 38-44.
[http://dx.doi.org/10.1111/tri.13037] [PMID: 28833714]
[32]
Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307(3): 283-93.
[http://dx.doi.org/10.1001/jama.2011.2014] [PMID: 22253395]
[33]
Feng S, Bucuvalas J. Tolerance after liver transplantation: Where are we? Liver Transpl 2017; 23(12): 1601-14.
[http://dx.doi.org/10.1002/lt.24845] [PMID: 28834221]

Rights & Permissions Print Cite
Article Metrics
29
4
© 2024 Bentham Science Publishers | Privacy Policy